期刊
KIDNEY INTERNATIONAL
卷 92, 期 2, 页码 297-305出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2017.04.019
关键词
-
资金
- KDIGO
- Abbvie
- Achillion
- Akebia Therapeutics
- Alexion
- Amgen
- AstraZeneca
- Bayer HealthCare
- Fresenius Medical Care
- KBP Biosciences
- Keryx Biopharmaceuticals
- Merck
- Omeros
- Relypsa
- Roche
- Vifor Fresenius Medical Care Renal Pharma
- Medical Research Council [MC_U137686853, MC_UU_12026/5, MC_UU_12026/4, MC_UU_12026/6] Funding Source: researchfish
- Steno Diabetes Center Copenhagen (SDCC) [SDCC 3.A Complications] Funding Source: researchfish
- MRC [MC_U137686853, MC_UU_12026/4, MC_UU_12026/5, MC_UU_12026/6] Funding Source: UKRI
Despite the high costs of treatment of people with kidney disease and associated comorbid conditions, the amount of reliable information available to guide the care of such patients is very limited. Some treatments have been assessed in randomized trials, but most such trials have been too small to detect treatment effects of a magnitude that would be realistic to achieve with a single intervention. Therefore, KDIGO convened an international, multidisciplinary controversies conference titled Challenges in the Conduct of Clinical Trials in Nephrology to identify the key barriers to conducting trials in patients with kidney disease. The conference began with plenary talks focusing on the key areas of discussion that included appropriate trial design (covering identification and evaluation of kidney and nonkidney disease outcomes) and sensible trial execution (with particular emphasis on streamlining both design and conduct). Break out group discussions followed in which the key areas of agreement and remaining controversy were identified. Here we summarize the main findings from the conference and set out a range of potential solutions. If followed, these solutions could ensure future trials among people with kidney disease are sufficiently robust to provide reliable answers and are not constrained by inappropriate complexities in design or conduct.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据